Clinical and pharmacological basis of the use of testosterone drugs for hormonal replacement therapy for hypogonadism in men
https://doi.org/10.14341/omet12850
Abstract
Hypogonadism is a condition associated with a decrease in the functional activity of the testicles, accompanied by a decrease in the level of androgens and (or) a violation of the process of spermatogenesis. It is known that androgens and their main representative, testosterone, are of fundamental importance for the development and maintenance of the reproductive and sexual functions of the male reproductive system. At the same time, low testosterone levels are associated with both reproductive and metabolic disorders, including phosphorus-calcium, fat, carbohydrate, and protein metabolism. In addition, to date, data have been accumulated on the correlation of hypogonadism with cardiovascular diseases, which once again emphasizes the problem of testosterone deficiency, especially for patients of the middle and older age groups. However, carrying out testosterone replacement therapy always requires a strict and competent choice of a «target audience» among patients from a specialist. Today, on the pharmaceutical market, there is a wide arsenal of testosterone-containing drugs in various forms for use, which have an unequal «efficacy-safety» profile. In this review, we have analyzed modern approaches to the diagnosis and treatment of hypogonadism, the selection of a target group of patients to obtain the most effective and safe treatment outcome and described testosterone preparations and their dosage forms with potential advantages and disadvantages. Thus, the information presented in the article is aimed at optimizing the management of men with hypogonadism.
About the Authors
N. I. Volkova
Rostov state medical university
Russian Federation
Russian Federation
Natalya I. Volkova, MD, PhD, Professor
eLibrary SPIN: 3146-8337
Rostov-on-Don, Nachichevansky street, 29
A. V. Safronenko
Rostov state medical university
Russian Federation
Russian Federation
Andrey V. Safronenko, MD, PhD, Associate
eLibrary SPIN: 3448-9574
Rostov-on-Don
E. V. Gantsgorn
Rostov state medical university
Russian Federation
Russian Federation
Elena V. Gantsgorn, MD, PhD, Associate Professor
eLibrary SPIN: 4797-6070
Rostov-on-Don
Yu. S. Degtyareva
Rostov state medical university
Russian Federation
Russian Federation
Yuliya S. Degtyareva, MD, postgraduate student
eLibrary SPIN: 8935-5325
Rostov-on-Don
References
1. Dedov II, Melnichenko GA, Rozhivanov RV, et al. Clinical guide diagnisis and treatment gipogonadism (geficit of testosteron). The project. Problems of Endocrinology. 2015;61(5):60-71. (In Russ). doi: https://doi.org/10.14341/probl20156560-71
2. Demidova TYu, Skuridina DV. Testosterone transdermal gels for endocrine disorders from the viewpoint of evidence-based medicine. Russkij medicinskij zhurnal. Medicinskoe obozrenie. 2019;3(10-2);96-100. (In Russ.).
3. Tischovskii SV, Nikonova LV. Male hypogonadism: features of diagnosis and treatment. Lechebnoe delo: nauchnopracticheskii gurnal. 2021;2(77):41-48. (In Russ.).
4. Dohle (Chair) GR, Arver S, Bettocchi C, Jones TH, et al. EAU Guidelines on Male Hypogonadism. European Association of Urology; 2016. 26 p.
5. Ametov AS, Pashova EYu. Testosterone therapy evolution. New preparations — new benefits. Endocrinologia: Novosti. Mneniya. Obuchenie. 2017;2(19):55-65. (In Russ.).
6. Kalinchenko SYu, Tyuzikov IA, Vorslov LO, et al. A Prolonged Release Injectable Testosterone Undecanoate for Treatment of Male Hypogonadism: a 10-Year Experience of Clinical Usage — from a Story of Development to the Modern Evidence-Based Efficacy and Safety. Effektivnaya farmakoterapiya. 2015;35:24-33. (In Russ.).
7. Arver S, Stief C, de la Rosette J, et al. A new 2% testosterone gel formulation: a comparison with currently available topical preparations. Andrology. 2018;6(3):396-407. doi: https://doi.org/10.1111/andr.12487
8. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. doi: https://doi.org/10.1016/j.juro.2018.03.115
9. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi: https://doi.org/10.1210/jc.2018-00229
10. Snyder PJ. Clinical features and diagnosis of male hypogonadism. UpToDate [Internet]. 2022. [cited 2022 Jun 01] Available from: https://www.uptodate.com/contents/clinical-features-and-diagnosis-ofmale-hypogonadism#!
11. Dedov II, Mokrysheva NG, Melnichenko GA, et al. Draft of Russian Clinical Practice Guidelines «Male hypogonadism». Obesity and metabolism. 2021;18(4):496-507. (In Russ.). doi: https://doi.org/10.14341/omet12817
12. Yeap BB, Wu FCW. Clinical practice update on testosterone therapy for male hypogonadism: Contrasting perspectives to optimize care. Clin Endocrinol (Oxf ). 2019;90(1):56-65. doi: https://doi.org/10.1111/cen.13888
13. Morgentaler A, Zitzmann M, Traish AM, et al. The consensus recommendations of a group of international experts on the fundamental concepts related to the issues of testosterone deficiency and its treatment. Obesity and metabolism. 2016;13(3):15-31. (In Russ.). doi: https://doi.org/10.14341/omet2016315-31
14. Efremov EA, Krasnyak SS. Vozmozhnye riski pri terapii testosteronom. Eksperimentalnaya i clinicheskaya urologia. 2017;1(1):90-96. (In Russ.).
15. Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19(1):64-69. doi: https://doi.org/10.3109/13685538.2015.1126573
16. Favilla V, Cimino S, Castelli T, et al. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. BJU Int. 2010;106(11):1700-1703. doi: https://doi.org/10.1111/j.1464-410X.2010.09459.x
17. Trifiro MD, Parsons JK, Palazzi-Churas K, et al. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int. 2010;105(11):1554-1559. doi: https://doi.org/10.1111/j.1464-410X.2009.09090.x
18. Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos N, et al. The Efficacy and Adverse Events of Testosterone Replacement Therapy in Hypogonadal Men: A Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab. 2018;103(5):1745-1754. doi: https://doi.org/10.1210/jc.2018-00404
19. Fernández-Balsells MM, Murad MH, Lane M. et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575. doi: https://doi.org/10.1210/jc.2009-2575
20. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. doi: https://doi.org/10.1056/NEJMoa1506119
21. Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA. 2017;317(7):708-716. doi: https://doi.org/10.1001/jama.2016.21043
22. Diem SJ, Greer NL, MacDonald R, et al. Efficacy and Safety of Testosterone Treatment in Men: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Ann Intern Med. 2020;172(2):105-118. doi: https://doi.org/10.7326/M19-0830
23. Al-Sharefi A, Quinton R. Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations. Endocrinol Metab (Seoul). 2020;35(3):526-540. doi: https://doi.org/10.3803/EnM.2020.760
24. Layton JB, Meier CR, Sharpless JL, et al. Comparative Safety of Testosterone Dosage Forms. JAMA Intern Med. 2015;175(7):1187. doi: https://doi.org/10.1001/jamainternmed.2015.1573
25. Petering RC, Brooks NA. Testosterone Therapy: Review of Clinical Applications. Am Fam Physician. 2017;96(7):441-449.
26. Corona G, Giagulli VA, Maseroli E, et al. Therapy of endocrine disease: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99-R116. doi: https://doi.org/10.1530/EJE-15-0262
27. Walker RF, Zakai NA, MacLehose RF, et al. Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism. JAMA Intern Med. 2020;180(2):190-197. doi: https://doi.org/10.1001/jamainternmed.2019.5135
28. Surampudi P, Swerdloff RS, Wang C. An update on male hypogonadism therapy. Expert Opin Pharmacother. 2014;15(9):1247-1264. doi: https://doi.org/10.1517/14656566.2014.913022
29. Kang D-Y, Li H-J. The Effect of Testosterone Replacement Therapy on Prostate-Specific Antigen (PSA) Levels in Men Being Treated for Hypogonadism. Medicine (Baltimore). 2015;94(3):e410. doi: https://doi.org/10.1097/MD.0000000000000410
30. Szeinbach SL, Enrique Seoane-Vazquez, Summers KH. Development of a men’s Preference for Testosterone Replacement Therapy (P-TRT) instrument. Patient Prefer Adherence. 2012;94(3):631. doi: https://doi.org/10.2147/PPA.S35840
31. Qaseem A, Horwitch CA, Vijan S, et al. Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2020;172(2):126. doi: https://doi.org/10.7326/M19-0882
32. Liu J-D, Wu Y-Q. Anabolic-androgenic steroids and cardiovascular risk. Chinese Medical Journal. 2019;132(18):2229-2236. doi: https://doi.org/10.1097/cm9.0000000000000407
33. Yeo S, Holl K, Peñaherrera N, et al. Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review. Clin Outcomes Res. 2021;13(2):31-38. doi: https://doi.org/10.2147/CEOR.S285434
34. Fadeeva EA. Efficiency of hormonal replacement therapy in boys with hypogonadism. Bulletin of Medical Internet Conferences. 2016;5:814 (In Russ.).
35. Swerdloff RS, Wang C, White WB, et al. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. J Clin Endocrinol Metab. 2020;105(8):2515-2531. doi: https://doi.org/10.1210/clinem/dgaa238
36. Patel M, Muthigi A, Ramasamy R. JATENZO®: Challenges in the development of oral testosterone. Int J Impot Res. 2021;105(8):2515-2531. doi: https://doi.org/10.1038/s41443-021-00461-4
37. Newell-Price J, Huatan H, Quirke J, et al. An oral lipidic native testosterone formulation that is absorbed independent of food. Eur J Endocrinol. 2021;185(5):607-615. doi: https://doi.org/10.1530/EJE-21-0606
38. DelConte A, Papangkorn K, Kim K, et al. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism. Andrology. 2022;10(4):669-676. doi: https://doi.org/10.1111/andr.13153
39. Bruno BJ, Vangara K, Kim K, et al. TLANDO, a Novel Oral TRT, Improves Sexual and Mental Domain Outcomes in Hypogonadal Men. J Endocr Soc. 2021;5(S1):A495-A496. doi: https://doi.org/10.1210/jendso/bvab048.1012
40. Papangkorn K, Vangara K, Bruno BJ, et al. Efficacy and Safety of TLANDO, A Novel Oral Easy to Prescribe and Use TRT Option. J Endocr Soc. 2021;5(S1):A486-A486. doi: https://doi.org/10.1210/jendso/bvab048.994
41. White WB, Bernstein JS, Rittmaster R, et al. Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men. J Clin Hypertens (Greenwich). 2021;23(7):1420-1430. doi: https://doi.org/10.1111/jch.14297
42. Saenger P, Steiner M. Oral testosterone undecanoate is an effective treatment for micropenis therapy. Pediatr Investig. 2021;5(4):323-324. doi: https://doi.org/10.1002/ped4.12304
43. Manuel ML. Patient Satisfaction After Switching to Oral Testosterone Undecanoate. [Internet]. 2022. [cited 2022 Aug 01] Available from: https://clinicaltrials.gov/ct2/show/NCT04983940?term=Oral+Testosterone+Undecanoate&draw=3&rank=12
44. Denmeade S, Sullivan R. Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer. [Internet]. 2022. [cited 2022 Aug 01] Available from: https://clinicaltrials.gov/ct2/show/NCT05081193?term=Oral+Testosterone+Undecanoate&draw=3&rank=11
45. Dhindsa S, Newman J. Testosterone Treatment in Men With Chronic Kidney Disease. [Internet]. 2022. [cited 2022 Aug 01] Available from: https://clinicaltrials.gov/ct2/show/NCT05249634?term=Oral+Testosterone+Undecanoate&draw=4&rank=28
Review
For citations:
Volkova N.I., Safronenko A.V., Gantsgorn E.V., Degtyareva Yu.S. Clinical and pharmacological basis of the use of testosterone drugs for hormonal replacement therapy for hypogonadism in men. Obesity and metabolism. 2022;19(2):233-241. (In Russ.) https://doi.org/10.14341/omet12850
Views:
30782
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
